Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4551-4560 Newer>

The Motley Fool February 1, 2008 Brian Lawler	AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs.
The Motley Fool January 31, 2008 Brian Lawler	When Nutraceuticals Attack After a failed phase 3 trial, Neurochem plans to market Alzhemed as a nutraceutical supplement.
The Motley Fool January 31, 2008 Brian Lawler	Prioritizing Millennium The FDA grants a speedy review for Millennium Pharmaceuticals's lead multiple myeloma drug.
The Motley Fool January 31, 2008 Brian Lawler	Don't Forget Roche Roche, the largest biopharma, by market capitalization, had a terrific 2007. Since it is not publicly listed on the major U.S. stock exchanges, the company never gets its fair share of attention.
The Motley Fool January 31, 2008 Brian Lawler	A Zettlement for Zyprexa? Eli Lilly may be close to resolving a government lawsuit over improper marketing.
The Motley Fool January 31, 2008 Brian Orelli	Investing Before the IPO If the idea of investing pre-IPO excites you, but you don't want to invest directly in a venture capital fund, there's a way to get in on the new company action by buying publicly traded companies: Many drug companies have venture capital arms.
The Motley Fool January 31, 2008 Rich Duprey	Candela Investors Burned Again The aesthetic-laser maker continues its string of disappointing quarters.
The Motley Fool January 31, 2008 Brian Orelli	Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug.
The Motley Fool January 31, 2008 Brian Lawler	Who Let the Docs Out? A leaked, confidential journal article could get Glaxo in hot water.
The Motley Fool January 31, 2008 Brian Orelli	One Last Look at Pre-Enhance Merck Investors show they care more about Merck's future than its Q4 results.
<Older 4551-4560 Newer> Return to current articles.